According to a recent LinkedIn post from Carta Healthcare, survey data from U.S. healthcare leaders points to strong support for AI as an adjunct to, rather than a replacement for, clinical expertise. The post cites figures such as 97% of respondents favoring AI in a supportive role and 64% seeing the most value when AI accelerates tasks while clinicians validate results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes concerns around risk, with 74% highlighting misinterpretation of complex clinical data without clinician involvement and 67% identifying human review as the top driver of trust in AI outputs. For investors, these findings suggest sustained demand for AI tools that embed human-in-the-loop workflows, potentially benefiting vendors like Carta Healthcare that position their products around clinician oversight and defensible risk management in AI-enabled care delivery.